Daniel, S. K.
Sullivan, K. M.
Dickerson, L. K.
van den Bijgaart, R. J. E.
Utria, A. F.
Labadie, K. P.
Kenerson, H. L.
Jiang, X.
Smythe, K. S.
Campbell, J. S.
Pierce, R. H.
Kim, T. S.
Riehle, K. J.
Yeung, R. S.
Carter, J. A.
Barry, K. C.
Pillarisetty, V. G.
Funding for this research was provided by:
Fibrolamellar Cancer Foundation
St. Baldrick's Foundation
U.S. Department of Defense (CA180067)
Article History
Received: 26 October 2023
Accepted: 26 February 2024
First Online: 1 March 2024
Competing interests
: VGP is a member of the scientific advisory board for TriSalus Life Sciences. He served as a consultant for Merck & Company in 2018, GlaxoSmithKline in 2019, Imvax in 2019, Takeda in 2020, Umoja and Sensei in 2022. He has previously had research funding from AstraZeneca, Ipsen, Merck, NGM, and OncoResponse. No other disclosures. All other authors has no competing interest.